FDA puts clinical hold on Biosciences gene therapy trial for Duchenne muscular dystrophy over toxicity concerns – Genetic Literacy Project
Genetic Literacy Project |
FDA puts clinical hold on Biosciences gene therapy trial for Duchenne muscular dystrophy over toxicity concerns
Genetic Literacy Project Concerns over the dosing of patients in IGNITE DMD led to gene therapy pioneer James M. Wilson, M.D., Ph.D., resigning from Solid's Scientific Advisory Board. According to an amended IPO filing, Dr. Wilson's resignation followed “emerging concerns … |
